Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.

Polypharmacy is associated with poor clinical outcomes following COVID-19 infection among patients with type 2 diabetes.